Distant Metastasis in Patients with Myxofibrosarcoma

Overview

Journal Ups J Med Sci

Specialty General Medicine

Date 2017 Aug 18

PMID 28814152

Citations 18

Authors

Hiroyuki Tsuchie

Mitsunori Kaya

Hiroyuki Nagasawa

Makoto Emori

Yasutaka Murahashi

Emi Mizushima

Naohisa Miyakoshi

Toshihiko Yamashita

Yoichi Shimada

Affiliations

Soon will be listed here.

Abstract

Purpose: A clinical feature of myxofibrosarcoma is local recurrence, but knowledge about distant metastasis is sparse. We evaluated the tendency of clinical and histological features of metastasis in myxofibrosarcoma patients.

Methods: Fifty-eight patients with myxofibrosarcoma were treated in our hospitals, and a total of 16 consecutive patients with distant metastases were included in this retrospective study (9 males and 7 females, with a mean age of 77 years). Because there was no patient complicated by both lung and lymph node metastases, we compared the age, sex, tumor size and location, French Federation of Cancer Centers Sarcoma Group (FNCLCC) grade, American Joint Committee on Cancer (AJCC) stage, and times of the first metastasis from the initial examination between the lung and lymph node groups. In addition, we examined factors affecting the prognosis.

Results: The median follow-up period was 42.9 months (range 8-142). Eleven of 16 patients developed pulmonary metastases. The sites of extra pulmonary metastases were the lymph nodes in 5 patients, bone in 1, subcutaneous in 1, intramuscular in 1, and peritoneum in 1. The median time for patients to develop distant metastases was 17.4 months (range 0-59). The time until the onset of the first metastasis in the lung metastasis group was significantly shorter than in the lymph node group (p < 0.05). Also, the survival rate in the lymph node metastasis group was better than in the lung metastasis group (p < 0.05).

Conclusions: Not only lung metastasis but also lymph node metastasis occurs frequently in myxofibrosarcoma patients. Myxofibrosarcoma with lung metastasis is more aggressive than the type with lymph node metastasis.

Citing Articles

Giant Myxofibrosarcoma in the Lower Limb: An Overview of Diagnostic and Clinical Management.

Ene R, Dimitriu A, Peride I, Tiglis M, Popescu E, Georgescu E Diagnostics (Basel). 2024; 14(12).

PMID: 38928713 PMC: 11202561. DOI: 10.3390/diagnostics14121298.

Localized Myxofibrosarcoma: A Retrospective Analysis of Primary Therapy and Prognostic Factors in 134 Patients in a Single Institution.

Pogkas A, Reichardt P, Tunn P, Niethard M, Werner M, Ghani S Oncologist. 2023; 29(4):e544-e552.

PMID: 38141181 PMC: 10994258. DOI: 10.1093/oncolo/oyad332.

Modeling Myxofibrosarcoma: Where Do We Stand and What Is Missing?.

Lucarelli E, De Vita A, Bellotti C, Frisoni T, Vanni S, Guerrieri A Cancers (Basel). 2023; 15(21).

PMID: 37958307 PMC: 10650645. DOI: 10.3390/cancers15215132.

Biology and Management of High-Grade Myxofibrosarcoma: State of the Art and Future Perspectives.

Nishio J, Nakayama S Diagnostics (Basel). 2023; 13(19).

PMID: 37835765 PMC: 10572210. DOI: 10.3390/diagnostics13193022.

Tislelizumab immunotherapy combined with chemotherapy in the treatment of a patient with primary anterior mediastinal undifferentiated pleomorphic sarcoma with high PD-L1 expression: A case report and literature review.

Yang H, Qin Z, He X, Xue Q, Zhou H, Sun J Front Oncol. 2023; 13:1110997.

PMID: 37091183 PMC: 10113508. DOI: 10.3389/fonc.2023.1110997.

References

Lin C, Chou S, Li C, Tsai K, Chen W, Hsiung C . Prognostic factors of myxofibrosarcomas: implications of margin status, tumor necrosis, and mitotic rate on survival. J Surg Oncol. 2006; 93(4):294-303. DOI: 10.1002/jso.20425. View

Coindre J, Terrier P, Bui N, Bonichon F, Collin F, Le Doussal V . Prognostic factors in adult patients with locally controlled soft tissue sarcoma. A study of 546 patients from the French Federation of Cancer Centers Sarcoma Group. J Clin Oncol. 1996; 14(3):869-77. DOI: 10.1200/JCO.1996.14.3.869. View

Look Hong N, Hornicek F, Raskin K, Yoon S, Szymonifka J, Yeap B . Prognostic factors and outcomes of patients with myxofibrosarcoma. Ann Surg Oncol. 2012; 20(1):80-6. PMC: 3837421. DOI: 10.1245/s10434-012-2572-3. View

Waters B, Panicek D, Lefkowitz R, Antonescu C, Healey J, Athanasian E . Low-grade myxofibrosarcoma: CT and MRI patterns in recurrent disease. AJR Am J Roentgenol. 2007; 188(2):W193-8. DOI: 10.2214/AJR.05.1130. View

Behranwala K, AHern R, Omar A, Thomas J . Prognosis of lymph node metastasis in soft tissue sarcoma. Ann Surg Oncol. 2004; 11(7):714-9. DOI: 10.1245/ASO.2004.04.027. View

Riouallon G, Larousserie F, Pluot E, Anract P . Superficial myxofibrosarcoma: assessment of recurrence risk according to the surgical margin following resection. A series of 21 patients. Orthop Traumatol Surg Res. 2013; 99(4):473-7. DOI: 10.1016/j.otsr.2012.11.020. View

Manoso M, Pratt J, Healey J, Boland P, Athanasian E . Infiltrative MRI pattern and incomplete initial surgery compromise local control of myxofibrosarcoma. Clin Orthop Relat Res. 2006; 450:89-94. DOI: 10.1097/01.blo.0000229292.98850.14. View

Mutter R, Singer S, Zhang Z, Brennan M, Alektiar K . The enigma of myxofibrosarcoma of the extremity. Cancer. 2011; 118(2):518-27. PMC: 3360945. DOI: 10.1002/cncr.26296. View

Haglund K, Raut C, Nascimento A, Wang Q, George S, Baldini E . Recurrence patterns and survival for patients with intermediate- and high-grade myxofibrosarcoma. Int J Radiat Oncol Biol Phys. 2010; 82(1):361-7. DOI: 10.1016/j.ijrobp.2010.08.042. View

10.

Mazeron J, Suit H . Lymph nodes as sites of metastases from sarcomas of soft tissue. Cancer. 1987; 60(8):1800-8. DOI: 10.1002/1097-0142(19871015)60:8<1800::aid-cncr2820600822>3.0.co;2-n. View

11.

Huang H, Lal P, Qin J, Brennan M, Antonescu C . Low-grade myxofibrosarcoma: a clinicopathologic analysis of 49 cases treated at a single institution with simultaneous assessment of the efficacy of 3-tier and 4-tier grading systems. Hum Pathol. 2004; 35(5):612-21. DOI: 10.1016/j.humpath.2004.01.016. View

12.

Riad S, Griffin A, Liberman B, Blackstein M, Catton C, Kandel R . Lymph node metastasis in soft tissue sarcoma in an extremity. Clin Orthop Relat Res. 2004; (426):129-34. DOI: 10.1097/01.blo.0000141660.05125.46. View

13.

Sanfilippo R, Miceli R, Grosso F, Fiore M, Puma E, Pennacchioli E . Myxofibrosarcoma: prognostic factors and survival in a series of patients treated at a single institution. Ann Surg Oncol. 2010; 18(3):720-5. DOI: 10.1245/s10434-010-1341-4. View

14.

Weingrad D, Rosenberg S . Early lymphatic spread of osteogenic and soft-tissue sarcomas. Surgery. 1978; 84(2):231-40. View

15.

Kikuta K, Kubota D, Yoshida A, Suzuki Y, Morioka H, Toyama Y . An analysis of factors related to recurrence of myxofibrosarcoma. Jpn J Clin Oncol. 2013; 43(11):1093-104. DOI: 10.1093/jjco/hyt119. View

16.

Dewan V, Darbyshire A, Sumathi V, Jeys L, Grimer R . Prognostic and survival factors in myxofibrosarcomas. Sarcoma. 2012; 2012:830879. PMC: 3379161. DOI: 10.1155/2012/830879. View

17.

Skinner K, Eilber F . Soft tissue sarcoma nodal metastases: biologic significance and therapeutic considerations. Surg Oncol Clin N Am. 1996; 5(1):121-7. View

18.

Kaya M, Wada T, Nagoya S, Yamashita T . Bone and/or joint attachment is a risk factor for local recurrence of myxofibrosarcoma. J Orthop Sci. 2011; 16(4):413-7. DOI: 10.1007/s00776-011-0100-0. View

19.

Fong Y, Coit D, Woodruff J, Brennan M . Lymph node metastasis from soft tissue sarcoma in adults. Analysis of data from a prospective database of 1772 sarcoma patients. Ann Surg. 1993; 217(1):72-7. PMC: 1242736. DOI: 10.1097/00000658-199301000-00012. View